High-Affinity Probe (HAP) technology provides insights into drug binding site accessibility on tumor tissues, offering valuable data for physicians exploring potential treatment options for patients with limited or exhausted choices. By profiling the interaction between approved therapies and a patient's tumor at the molecular level, HAPs generate research-driven insights into potential drug matches based on tumor-specific characteristics. While this technology is designed for research use only and is not extensively clinically validated yet*, it can inform discussions between physicians and patients about personalized treatment approaches, enabling data-driven exploration of alternative therapies within a research framework.
Please reach out to us to determine if your patients qualify for Patient-Specific Drug Affinity Profiling . Select patients may also qualify for free testing through ongoing research initiatives. Contact us today to discuss eligibility and explore how this service can support personalized care for your patients.
*This assay is intended for research use only (RUO) and is not validated for diagnostic or therapeutic purposes at this point. Any use of this technology in a clinical setting is exploratory and at the sole discretion of the physician.
We invite you to connect with us to explore how our High-Affinity Probe (HAP) technology can address your research and clinical objectives. Whether your focus is on custom probe development, enhancing clinical trial strategies, or advancing therapeutic profiling, our team is ready to provide tailored support and expert guidance.
Contact us to discuss your specific needs, request detailed information, or learn more about how HAP technology can contribute to your success in drug development and precision oncology.
